A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction

Completed · Phase 1

Conditions studied: Carcinoma, Hepatocellular

In brief

The primary purpose of this protocol is to determine the effect of BMS-582664 on patients with hepatocellular carcinoma with varying levels of hepatic impairment

Key facts

Study ID

NCT00437424

Run by

Bristol-Myers Squibb

People needed

24

Starts

2007-07-01

Expected to finish

2010-06-01

Last updated by the study team

2011-05-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects with a biopsy proven advanced solid tumor
• Subjects with a biopsy proven diagnosis of hepatocellular carcinoma conforming to child pugh classifications A, B, or C

Where it is running

• University Of Alabama At Birmingham — Birmingham, Alabama, United States
• Usc/Norris Comprehensive Cancer Center — Los Angeles, California, United States
• Case Western Reserve University — Clleveland, Ohio, United States
• South Texas Accelerated Research Therapeutics, Llc — San Antonio, Texas, United States
• Local Institution — Seville, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.